Perspectives

Mitigating global fraud and corruption risks in life sciences R&D

Forensic Investigations

Life sciences companies operate in a global industry, which intensifies the potential for fraud and corruption-related risks as identified in the Foreign Corrupt Practices Act (FCPA), the Physician Payments Sunshine Act, the Bribery Act 2010 (UK Bribery Act), and other global legislation. While regulatory scrutiny historically has focused on manufacturers’ commercialization activities, recent trends suggest that research and development (R&D) activities also have come to the attention of regulators.

Five steps to mitigate R&D fraud and corruption

Too often, life sciences companies assume that using third parties to oversee offshore R&D activities mitigates risks. However, even though responsibilities may be delegated, accountability is not. The life sciences company is ultimately accountable for outcomes.


Download this article to learn five key steps that can help life sciences companies mitigate R&D fraud and corruption risks

While regulatory scrutiny historically has focused on manufacturers’ commercialization activities, recent trends suggest that research and development (R&D) activities also have come to the attention of regulators.

Did you find this useful?